Atika Capital Management Position In Aerie Pharmaceuticals (AERI) Was Raised; Springbok Capital Management Has Trimmed Bio Rad Labs (BIO) Stake by $740,894

April 17, 2018 - By Richard Conner

Bio-Rad Laboratories, Inc. (NYSE:BIO) Logo

Brad Farber increased its stake in Aerie Pharmaceuticals Inc (AERI) by 15.09% based on its latest 2017Q4 regulatory filing with the SEC. Atika Capital Management Llc bought 8,600 shares as the company’s stock declined 12.77% with the market. The hedge fund run by Brad Farber held 65,600 shares of the health care company at the end of 2017Q4, valued at $3.92 million, up from 57,000 at the end of the previous reported quarter. Atika Capital Management Llc who had been investing in Aerie Pharmaceuticals Inc for a number of months, seems to be bullish on the $2.14 billion market cap company. The stock increased 1.79% or $0.95 during the last trading session, reaching $54.05. About 58,916 shares traded. Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has risen 16.25% since April 17, 2017 and is uptrending. It has outperformed by 4.70% the S&P500.

Gavin Saitowitz decreased its stake in Bio Rad Labs Inc (BIO) by 30.12% based on its latest 2017Q4 regulatory filing with the SEC. Springbok Capital Management Llc sold 3,113 shares as the company’s stock rose 2.21% while stock markets declined. The hedge fund run by Gavin Saitowitz held 7,222 shares of the capital goods company at the end of 2017Q4, valued at $1.72M, down from 10,335 at the end of the previous reported quarter. Springbok Capital Management Llc who had been investing in Bio Rad Labs Inc for a number of months, seems to be less bullish one the $7.84 billion market cap company. The stock increased 0.24% or $0.62 during the last trading session, reaching $262.75. About 41,159 shares traded. Bio-Rad Laboratories, Inc. (NYSE:BIO) has risen 25.02% since April 17, 2017 and is uptrending. It has outperformed by 13.47% the S&P500.

Springbok Capital Management Llc, which manages about $1.29B and $1.25 billion US Long portfolio, upped its stake in Extraction Oil And Gas Inc by 56,348 shares to 59,250 shares, valued at $848,000 in 2017Q4, according to the filing. It also increased its holding in Kilroy Rlty Corp (NYSE:KRC) by 10,134 shares in the quarter, for a total of 27,463 shares, and has risen its stake in Pioneer Nat Res Co (NYSE:PXD).

Investors sentiment increased to 1.13 in Q4 2017. Its up 0.35, from 0.78 in 2017Q3. It increased, as 23 investors sold BIO shares while 89 reduced holdings. 44 funds opened positions while 82 raised stakes. 18.57 million shares or 0.31% more from 18.51 million shares in 2017Q3 were reported. Bbva Compass Bank & Trust Inc has 4,180 shares. Ledyard Commercial Bank stated it has 114 shares or 0% of all its holdings. Ameriprise, Minnesota-based fund reported 65,743 shares. Plante Moran Fincl Advisors Lc accumulated 8 shares or 0% of the stock. Advisor Prns Limited Liability Company holds 926 shares or 0.04% of its portfolio. Menta Cap Limited Liability Co stated it has 2,502 shares. Brinker Incorporated stated it has 0.04% in Bio-Rad Laboratories, Inc. (NYSE:BIO). Balyasny Asset Mgmt Limited Liability Corp stated it has 0% of its portfolio in Bio-Rad Laboratories, Inc. (NYSE:BIO). Wells Fargo And Co Mn owns 625,032 shares. Nelson Van Denburg Campbell Wealth Mngmt Group Ltd Company holds 975 shares. Aperio Gru Ltd stated it has 18,892 shares. State Bank Of America De holds 0.01% of its portfolio in Bio-Rad Laboratories, Inc. (NYSE:BIO) for 330,418 shares. Fmr Lc has 0% invested in Bio-Rad Laboratories, Inc. (NYSE:BIO) for 144,095 shares. Weaver C Barksdale & holds 46 shares. Tudor Investment Corp Et Al has 0.02% invested in Bio-Rad Laboratories, Inc. (NYSE:BIO).

Analysts await Bio-Rad Laboratories, Inc. (NYSE:BIO) to report earnings on May, 3. They expect $0.93 EPS, up 126.83% or $0.52 from last year’s $0.41 per share. BIO’s profit will be $27.74 million for 70.63 P/E if the $0.93 EPS becomes a reality. After $1.50 actual EPS reported by Bio-Rad Laboratories, Inc. for the previous quarter, Wall Street now forecasts -38.00% negative EPS growth.

Since December 14, 2017, it had 0 buys, and 1 insider sale for $1.24 million activity.

Among 5 analysts covering Bio-Rad Laboratories (NYSE:BIO), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Bio-Rad Laboratories had 20 analyst reports since August 7, 2015 according to SRatingsIntel. Jefferies maintained Bio-Rad Laboratories, Inc. (NYSE:BIO) on Wednesday, April 12 with “Buy” rating. The stock has “Outperform” rating by Wells Fargo on Wednesday, February 28. The stock of Bio-Rad Laboratories, Inc. (NYSE:BIO) has “Buy” rating given on Wednesday, September 7 by Jefferies. The stock has “Buy” rating by Wells Fargo on Tuesday, March 20. Jefferies maintained the shares of BIO in report on Wednesday, September 27 with “Buy” rating. The stock of Bio-Rad Laboratories, Inc. (NYSE:BIO) has “Buy” rating given on Friday, April 28 by Jefferies. The stock has “Neutral” rating by CL King on Friday, February 16. The stock has “Hold” rating by C.L. King on Friday, February 16. The rating was upgraded by Deutsche Bank on Wednesday, June 28 to “Buy”. The rating was maintained by Wells Fargo with “Buy” on Wednesday, November 29.

Investors sentiment decreased to 1.2 in 2017 Q4. Its down 0.53, from 1.73 in 2017Q3. It worsened, as 23 investors sold AERI shares while 48 reduced holdings. 21 funds opened positions while 64 raised stakes. 34.86 million shares or 1.29% more from 34.42 million shares in 2017Q3 were reported. Northern invested in 0.01% or 426,200 shares. Goldman Sachs Incorporated holds 0% or 157,977 shares in its portfolio. United Cap Financial Advisers Limited Liability Corporation holds 5,515 shares or 0% of its portfolio. Us Retail Bank De reported 764 shares. Partner Fund Management Ltd Partnership, a California-based fund reported 2.61 million shares. Wells Fargo & Mn reported 22,991 shares. Alyeska Lp stated it has 0.07% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Moreover, Citigroup Inc has 0% invested in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Commercial Bank Of Ny Mellon reported 613,305 shares. Columbus Circle Investors, Connecticut-based fund reported 593,086 shares. Perigon Wealth Management Limited Liability reported 1,098 shares. Georgia-based Voya Invest Limited has invested 0.05% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). State Street Corp owns 803,008 shares for 0% of their portfolio. Moreover, Ameriprise Incorporated has 0.01% invested in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) for 295,402 shares. Sei Invests Co has 0% invested in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI).

Among 15 analysts covering Aerie Pharmaceuticals (NASDAQ:AERI), 15 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aerie Pharmaceuticals had 50 analyst reports since August 7, 2015 according to SRatingsIntel. The stock has “Buy” rating by Cantor Fitzgerald on Friday, August 7. The stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has “Buy” rating given on Tuesday, November 1 by Aegis Capital. The stock has “Buy” rating by Cantor Fitzgerald on Wednesday, February 28. The firm has “Buy” rating given on Wednesday, January 24 by Canaccord Genuity. The firm has “Strong Buy” rating by Raymond James given on Wednesday, September 14. The firm has “Buy” rating by Needham given on Friday, September 15. As per Tuesday, August 1, the company rating was maintained by Canaccord Genuity. The stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) earned “Buy” rating by TH Capital on Friday, February 17. The firm earned “Buy” rating on Thursday, July 27 by Stifel Nicolaus. H.C. Wainwright maintained the stock with “Buy” rating in Thursday, March 1 report.

Bio-Rad Laboratories, Inc. (NYSE:BIO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: